Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Monte Rosa Therapeutics (GLUE) Return on Sales: 2024-2025

Historic Return on Sales for Monte Rosa Therapeutics (GLUE) over the last 1 years, with Sep 2025 value amounting to 0.12%.

  • Monte Rosa Therapeutics' Return on Sales was N/A to 0.12% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.12%, marking a year-over-year change of. This contributed to the annual value of -0.96% for FY2024, which is N/A change from last year.
  • Per Monte Rosa Therapeutics' latest filing, its Return on Sales stood at 0.12% for Q3 2025, which was down 15.04% from 0.14% recorded in Q2 2025.
  • Over the past 5 years, Monte Rosa Therapeutics' Return on Sales peaked at 0.14% during Q2 2025, and registered a low of -0.96% during Q4 2024.
  • Over the past 2 years, Monte Rosa Therapeutics' median Return on Sales value was 0.08% (recorded in 2025), while the average stood at -0.17%.